Search - tctmd.com

Displaying 61 - 80 of 89

Sort: Relevancy | Date

Presentation TCT 2016

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Presenter: Jonathan M. Hill, Christoph K. Naber, Manel Sabate

November 01, 2016

Presentation TCT 2016

TCT 3: Pretreatment With P2Y12 Receptor Antagonists Is Not Associated With Improved Patency of Infarct Related-Artery in STEMI A Report from SCAAR

Presenter: Andreas Baumbach, Kurt Huber, Elmir Omerovic

October 31, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White, Philippe Généreux

October 15, 2015

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Intravenous P2Y12 Inhibition: Role for Cangrelor

Presenter: George D. Dangas, Paul A. Gurbel, Robert A. Harrington

October 13, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

Preloading P2Y12 Antagonists in NSTE-ACS and STEMI: Safe and Effective? What Regimens?

Presenter: Dominick J. Angiolillo

September 13, 2014

News Conference News TCT 2014

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Todd Neale

September 13, 2014

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

Presentation TCT 2013

Rapid-Acting Potent IV P2Y12 Inhibition: Evolution or Revolution?

Presenter: Robert Harrington

October 27, 2013

Presentation TCT 2013

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Presenter: Rakesh Sharma, Stephen Erickson, Rohit Sharma, Hanumanth Reddy, Donald Voelker, Harvinder Dod, Vibhuti Singh, james Marsh

January 31, 2013

Presentation TCT 2012

Should P2Y12 Antagonists Be Continued Through CABG in Patients with ACS?

Presenter: Adnan Kastrati

October 24, 2012

Advertisement

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

TCT 3: Pretreatment With P2Y12 Receptor Antagonists Is Not Associated With Improved Patency of Infarct Related-Artery in STEMI A Report from SCAAR

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor IV: Transitioning to Oral ADP Antagonists

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

Intravenous P2Y12 Inhibition: Role for Cangrelor

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Preloading P2Y12 Antagonists in NSTE-ACS and STEMI: Safe and Effective? What Regimens?

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Studies Find Differing Benefits of Platelet, Genotype Testing

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

Rapid-Acting Potent IV P2Y12 Inhibition: Evolution or Revolution?

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Should P2Y12 Antagonists Be Continued Through CABG in Patients with ACS?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content